Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Wojciech Jurczak"'
Autor:
Jennifer R. Brown, Paolo Ghia, Wojciech Jurczak, Brad S. Kahl, Nicole Lamanna, Tadeusz Robak, Mazyar Shadman, Constantine S. Tam, Lugui Qiu, Jason Paik, Tommi Salmi, Liping Wang, Jun Zhang, Meng Zhang, Aileen Cohen, Han Ma, Alessandra Tedeschi
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/756c4a609f914095b5f6e8517eb0f99d
Autor:
Johannes Duell, Pau Abrisqueta, Marc Andre, Gianluca Gaidano, Eva Gonzales-Barca, Wojciech Jurczak, Nagesh Kalakonda, Anna Marina Liberati, Kami J Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Christian Kuffer, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
Tafasitamab, an anti-CD19 immunotherapy, is used with lenalidomide for patients with autologous stem cell transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma based on the results of the phase II L-MIND study (NCT02399085). We repo
Externí odkaz:
https://doaj.org/article/61775e7e540d41329d593e13a342ad7b
Autor:
Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, Richard R. Furman
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK se
Externí odkaz:
https://doaj.org/article/539d278310f84aa3955bb4b7eb5f3b1d
Autor:
Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles
Publikováno v:
Haematologica, Vol 999, Iss 1 (2021)
Not available.
Externí odkaz:
https://doaj.org/article/87ddd8a6674b4a1a85c63967777aba9a
Autor:
Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles
Publikováno v:
Haematologica, Vol 106, Iss 9 (2021)
Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study of patien
Externí odkaz:
https://doaj.org/article/d8d1ea0703764255af024006d6ad0b4a